Nanobiotix Stock Soars 12%, Marking a 945% Performance Over One Year
The stock of the French biotech company sharply accelerates at midday, driven by a very dynamic Parisian market and the response to the amendment approved by the FDA earlier this week. The price has crossed its technical resistance threshold.
A Soaring Session that Breaks the €33.50 Resistance
Nanobiotix jumps 12.1% to €32.62 at midday, up from €29.10 the previous day. The stock is challenging its identified resistance at €33.50 after having touched it. This movement is part of a very firm CAC 40, which is up 3.01% at 8,305 points during the session. The weekly gain reaches 15.1%, and 79.8% over three months. The price is well above the upper Bollinger band set at €29.82, a configuration that indicates a strong buying dynamic but also a state of technical overbought. The 50-day moving average, at €27.10, is now far exceeded. The RSI at 57 remains in the neutral zone, indicating that today's rise follows a breathing phase. The one-year performance now exceeds 945%, one of the strongest trajectories in the Parisian biotech sector.
FDA Approval of NANORAY-312 Fuels the Momentum
The movement extends the market's reaction to the FDA's acceptance of an amendment to the Phase 3 study protocol of NANORAY-312, announced on Monday. The amendment, filed by Johnson & Johnson as the global sponsor of the candidate JNJ-1900 (NBTXR3), concerns the analysis device of the trial dedicated to head and neck cancer. It could accelerate the development schedule. As a reminder, the biotech also presented preclinical data on its nanoprimer platform at the American Association for Cancer Research congress in April. The stock is part of a mixed European health sector this Wednesday: Sanofi is up 0.24% and Eurofins Scientific jumps 3.17%. No financial meetings are scheduled in the short term. The crossing of the resistance threshold of €33.50 remains the main technical reference.
